{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T17:25:42Z","timestamp":1786987542067,"version":"build-2736575974"},"reference-count":80,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,11,14]],"date-time":"2024-11-14T00:00:00Z","timestamp":1731542400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100014553","name":"Simon Spies Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100014553","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004046","name":"Karen Elise Jensen Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004046","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1016\/j.critrevonc.2024.104560","type":"journal-article","created":{"date-parts":[[2024,11,14]],"date-time":"2024-11-14T21:13:58Z","timestamp":1731618838000},"page":"104560","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["A systematic literature review on clonal evolution events preceding relapse in multiple myeloma"],"prefix":"10.1016","volume":"205","author":[{"given":"Maja Zimmer","family":"Jakobsen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rasmus Froberg","family":"Br\u00f8ndum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henrik","family":"Gregersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanne","family":"Due","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2488-435X","authenticated-orcid":false,"given":"Karen","family":"Dybk\u00e6r","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7463","key":"10.1016\/j.critrevonc.2024.104560_bib1","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1038\/nature12477","article-title":"Signatures of mutational processes in human cancer","volume":"500","author":"Alexandrov","year":"2013","journal-title":"Nature"},{"issue":"6","key":"10.1016\/j.critrevonc.2024.104560_bib2","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1182\/blood.2022017010","article-title":"Whole-genome analysis identifies novel drivers and high-risk double-hit events in relapsed\/refractory myeloma","volume":"141","author":"Ansari-Pour","year":"2023","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.critrevonc.2024.104560_bib3","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1016\/j.cell.2013.03.021","article-title":"Punctuated evolution of prostate cancer genomes","volume":"153","author":"Baca","year":"2013","journal-title":"Cell"},{"issue":"MAY)","key":"10.1016\/j.critrevonc.2024.104560_bib4","article-title":"Cell of origin and genetic alterations in the pathogenesis of multiple myeloma","volume":"10","author":"Barwick","year":"2019","journal-title":"Front. Immunol."},{"issue":"9","key":"10.1016\/j.critrevonc.2024.104560_bib5","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1182\/bloodadvances.2020003541","article-title":"Comprehensive CRISPR-Cas9 screens identify genetic determinants of drug responsiveness in multiple myeloma","volume":"5","author":"Bohl","year":"2021","journal-title":"Blood Adv."},{"issue":"1","key":"10.1016\/j.critrevonc.2024.104560_bib6","doi-asserted-by":"crossref","first-page":"2997","DOI":"10.1038\/ncomms3997","article-title":"Heterogeneity of genomic evolution and mutational profiles in multiple myeloma","volume":"5","author":"Bolli","year":"2014","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.critrevonc.2024.104560_bib7","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41467-018-05058-y","article-title":"Genomic patterns of progression in smoldering multiple myeloma","volume":"9","author":"Bolli","year":"2018","journal-title":"Nat. Commun."},{"issue":"7339","key":"10.1016\/j.critrevonc.2024.104560_bib8","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1038\/nature09837","article-title":"Initial genome sequencing and analysis of multiple myeloma","volume":"471","author":"Chapman","year":"2011","journal-title":"Nature"},{"issue":"3","key":"10.1016\/j.critrevonc.2024.104560_bib9","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1038\/s41591-021-01232-w","article-title":"Identification of resistance pathways and therapeutic targets in relapsed multiple myeloma patients through single-cell sequencing","volume":"27","author":"Cohen","year":"2021","journal-title":"Nat. Med."},{"issue":"12","key":"10.1016\/j.critrevonc.2024.104560_bib10","doi-asserted-by":"crossref","first-page":"2636","DOI":"10.1038\/s41375-018-0153-6","article-title":"Multiple myeloma clonal evolution in homogeneously treated patients","volume":"32","author":"Corre","year":"2018","journal-title":"Leukemia"},{"issue":"7","key":"10.1016\/j.critrevonc.2024.104560_bib11","doi-asserted-by":"crossref","first-page":"2043","DOI":"10.1038\/s41375-020-01096-y","article-title":"Copy number evolution and its relationship with patient outcome\u2014an analysis of 178 matched presentation-relapse tumor pairs from the Myeloma XI trial","volume":"35","author":"Croft","year":"2021","journal-title":"Leukemia"},{"issue":"4","key":"10.1016\/j.critrevonc.2024.104560_bib12","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1038\/s41591-021-01245-5","article-title":"Homozygous BCMA gene deletion in response to anti-BCMA CAR T cells in a patient with multiple myeloma","volume":"27","author":"Da Vi\u00e0","year":"2021","journal-title":"Nat. Med."},{"issue":"11","key":"10.1016\/j.critrevonc.2024.104560_bib13","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1038\/s43018-023-00625-9","article-title":"Acquired resistance to a GPRC5D-directed T-cell engager in multiple myeloma is mediated by genetic or epigenetic target inactivation","volume":"4","author":"Derrien","year":"2023","journal-title":"Nat. Cancer"},{"issue":"5","key":"10.1016\/j.critrevonc.2024.104560_bib14","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1038\/s41375-021-01130-7","article-title":"Positive selection as the unifying force for clonal evolution in multiple myeloma","volume":"35","author":"Diamond","year":"2021","journal-title":"Leukemia"},{"issue":"19","key":"10.1016\/j.critrevonc.2024.104560_bib15","first-page":"2359","article-title":"Tracking the evolution of therapy-related myeloid neoplasms using chemotherapy signatures","volume":"141","author":"Diamond","year":"2023","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.critrevonc.2024.104560_bib16","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1038\/s41375-018-0206-x","article-title":"Subclonal evolution in disease progression from MGUS\/SMM to multiple myeloma is characterised by clonal stability","volume":"33","author":"Dutta","year":"2019","journal-title":"Leukemia"},{"issue":"5","key":"10.1016\/j.critrevonc.2024.104560_bib17","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1182\/blood-2012-01-405977","article-title":"Whole-genome sequencing of multiple myeloma from diagnosis to plasma cell leukemia reveals genomic initiating events, evolution, and clonal tides","volume":"120","author":"Egan","year":"2012","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.critrevonc.2024.104560_bib18","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1586\/14737140.7.7.945","article-title":"Melphalan and its role in the management of patients with multiple myeloma","volume":"7","author":"Falco","year":"2007","journal-title":"Expert Rev. Anticancer Ther."},{"issue":"11","key":"10.1016\/j.critrevonc.2024.104560_bib19","first-page":"5659","article-title":"Branching clonal evolution patterns predominate mutational landscape in multiple myeloma","volume":"11","author":"Farswan","year":"2021","journal-title":"Am. J. Cancer Res."},{"issue":"9","key":"10.1016\/j.critrevonc.2024.104560_bib20","doi-asserted-by":"crossref","first-page":"3112","DOI":"10.1182\/blood-2007-02-069625","article-title":"Immunoglobulin gene rearrangements and the pathogenesis of multiple myeloma","volume":"110","author":"Gonz\u00e1lez","year":"2007","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.critrevonc.2024.104560_bib21","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1158\/2159-8290.CD-15-0439","article-title":"Evolutionary determinants of cancer","volume":"5","author":"Greaves","year":"2015","journal-title":"Cancer Discov."},{"issue":"7381","key":"10.1016\/j.critrevonc.2024.104560_bib22","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1038\/nature10762","article-title":"Clonal evolution in cancer","volume":"481","author":"Greaves","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.critrevonc.2024.104560_bib23","first-page":"1997","article-title":"ERK\/MAPK signalling pathway and tumorigenesis (Review)","author":"Guo","year":"2020","journal-title":"Exp. Ther. Med."},{"issue":"7","key":"10.1016\/j.critrevonc.2024.104560_bib24","doi-asserted-by":"crossref","DOI":"10.1002\/hem3.110","article-title":"Clonal competition assays identify fitness signatures in cancer progression and resistance in multiple myeloma","volume":"8","author":"Haertle","year":"2024","journal-title":"HemaSphere"},{"issue":"1","key":"10.1016\/j.critrevonc.2024.104560_bib25","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1158\/2159-8290.CD-21-1059","article-title":"Hallmarks of cancer: new dimensions","volume":"12","author":"Hanahan","year":"2022","journal-title":"Cancer Discov."},{"issue":"10","key":"10.1016\/j.critrevonc.2024.104560_bib26","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/s41408-020-00367-2","article-title":"An enhanced genetic model of relapsed IGH-translocated multiple myeloma evolutionary dynamics","volume":"10","author":"Hoang","year":"2020","journal-title":"Blood Cancer J."},{"issue":"21","key":"10.1016\/j.critrevonc.2024.104560_bib27","first-page":"5320","article-title":"Coexistence of aneuploid subclones within a myeloma cell line that exhibits clonal immunoglobulin gene rearrangement: clinical implications","volume":"53","author":"Jelinek","year":"1993","journal-title":"Cancer Res."},{"issue":"7","key":"10.1016\/j.critrevonc.2024.104560_bib28","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/cancers13071668","article-title":"Pathway-directed therapy in multiple myeloma","volume":"13","author":"John","year":"2021","journal-title":"Cancers"},{"issue":"7","key":"10.1016\/j.critrevonc.2024.104560_bib29","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.3324\/haematol.2018.202200","article-title":"Clonal evolution in myeloma: the impact of maintenance lenalidomide and depth of response on the genetics and sub-clonal structure of relapsed disease in uniformly treated newly diagnosed patients","volume":"104","author":"Jones","year":"2019","journal-title":"Haematologica"},{"issue":"September 2021)","key":"10.1016\/j.critrevonc.2024.104560_bib30","article-title":"Correlation of changes in subclonal architecture with progression in the MMRF CoMMpass study","volume":"23","author":"Kaur","year":"2022","journal-title":"Transl. Oncol."},{"issue":"5","key":"10.1016\/j.critrevonc.2024.104560_bib31","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1182\/blood-2012-01-405985","article-title":"Clonal competition with alternating dominance in multiple myeloma","volume":"120","author":"Keats","year":"2012","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.critrevonc.2024.104560_bib32","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.ccr.2007.07.003","article-title":"Promiscuous mutations activate the noncanonical NF-\u03baB pathway in multiple myeloma","volume":"12","author":"Keats","year":"2007","journal-title":"Cancer Cell"},{"issue":"10","key":"10.1016\/j.critrevonc.2024.104560_bib33","doi-asserted-by":"crossref","first-page":"3456","DOI":"10.1172\/JCI61188","article-title":"Molecular pathogenesis of multiple myeloma and its premalignant precursor","volume":"122","author":"Kuehl","year":"2012","journal-title":"J. Clin. Investig."},{"issue":"1","key":"10.1016\/j.critrevonc.2024.104560_bib34","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41467-020-17459-z","article-title":"Accelerated single cell seeding in relapsed multiple myeloma","volume":"11","author":"Landau","year":"2020","journal-title":"Nat. Commun."},{"issue":"22","key":"10.1016\/j.critrevonc.2024.104560_bib35","doi-asserted-by":"crossref","first-page":"5412","DOI":"10.1182\/blood-2008-12-194241","article-title":"Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study","volume":"113","author":"Landgren","year":"2009","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.critrevonc.2024.104560_bib36","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1200\/JCO.21.01987","article-title":"In multiple myeloma, high-risk secondary genetic events observed at relapse are present from diagnosis in tiny, undetectable subclonal populations","volume":"41","author":"Lannes","year":"2023","journal-title":"J. Clin. Oncol."},{"issue":"9","key":"10.1016\/j.critrevonc.2024.104560_bib37","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1038\/s41591-023-02491-5","article-title":"Mechanisms of antigen escape from BCMA- or GPRC5D-targeted immunotherapies in multiple myeloma","volume":"29","author":"Lee","year":"2023","journal-title":"Nat. Med."},{"issue":"1","key":"10.1016\/j.critrevonc.2024.104560_bib38","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12943-022-01648-z","article-title":"Malignant clonal evolution drives multiple myeloma cellular ecological diversity and microenvironment reprogramming","volume":"21","author":"Liang","year":"2022","journal-title":"Mol. Cancer"},{"issue":"1","key":"10.1016\/j.critrevonc.2024.104560_bib39","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1080\/10717544.2018.1474964","article-title":"Delivering crispr: a review of the challenges and approaches","volume":"25","author":"Lino","year":"2018","journal-title":"Drug Deliv."},{"issue":"1","key":"10.1016\/j.critrevonc.2024.104560_bib40","doi-asserted-by":"crossref","first-page":"2559","DOI":"10.1038\/s41467-021-22804-x","article-title":"Co-evolution of tumor and immune cells during progression of multiple myeloma","volume":"12","author":"Liu","year":"2021","journal-title":"Nat. Commun."},{"issue":"2","key":"10.1016\/j.critrevonc.2024.104560_bib41","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1038\/leu.2012.226","article-title":"Minor clone provides a reservoir for relapse in multiple myeloma","volume":"27","author":"Magrangeas","year":"2013","journal-title":"Leukemia"},{"issue":"2","key":"10.1016\/j.critrevonc.2024.104560_bib42","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1038\/nrclinonc.2016.122","article-title":"Genomic complexity of multiple myeloma and its clinical implications","volume":"14","author":"Manier","year":"2017","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2024.104560_bib43","doi-asserted-by":"crossref","first-page":"3835","DOI":"10.1038\/s41467-019-11680-1","article-title":"Genomic landscape and chronological reconstruction of driver events in multiple myeloma","volume":"10","author":"Maura","year":"2019","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.critrevonc.2024.104560_bib44","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.ccell.2014.12.001","article-title":"Biological and therapeutic impact of intratumor heterogeneity in cancer evolution","volume":"27","author":"McGranahan","year":"2015","journal-title":"Cancer Cell"},{"issue":"8","key":"10.1016\/j.critrevonc.2024.104560_bib45","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1038\/leu.2014.13","article-title":"Single-cell genetic analysis reveals the composition of initiating clones and phylogenetic patterns of branching and parallel evolution in myeloma","volume":"28","author":"Melchor","year":"2014","journal-title":"Leukemia"},{"issue":"7","key":"10.1016\/j.critrevonc.2024.104560_bib46","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.1038\/s41375-022-01597-y","article-title":"Clonal evolution after treatment pressure in multiple myeloma: heterogenous genomic aberrations and transcriptomic convergence","volume":"36","author":"Misund","year":"2022","journal-title":"Leukemia"},{"issue":"5","key":"10.1016\/j.critrevonc.2024.104560_bib47","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1016\/j.cell.2012.04.023","article-title":"The life history of 21 breast cancers","volume":"149","author":"Nik-Zainal","year":"2012","journal-title":"Cell"},{"issue":"4260","key":"10.1016\/j.critrevonc.2024.104560_bib48","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1126\/science.959840","article-title":"The clonal evolution of tumor cell populations","volume":"194","author":"Nowell","year":"1976","journal-title":"Sci. (N. Y., N. Y. )"},{"issue":"March","key":"10.1016\/j.critrevonc.2024.104560_bib49","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"88","author":"Page","year":"2021","journal-title":"Int. J. Surg."},{"issue":"11","key":"10.1016\/j.critrevonc.2024.104560_bib50","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.1038\/s43018-023-00637-5","article-title":"Myeloma evades T cell-engaging therapies","volume":"4","author":"Paiva","year":"2023","journal-title":"Nat. Cancer"},{"issue":"1","key":"10.1016\/j.critrevonc.2024.104560_bib51","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1002\/gcc.20114","article-title":"Cytogenetic manifestations of multiple myeloma heterogeneity","volume":"42","author":"Pantou","year":"2005","journal-title":"Genes, Chromosomes Cancer"},{"issue":"2","key":"10.1016\/j.critrevonc.2024.104560_bib52","doi-asserted-by":"crossref","first-page":"407","DOI":"10.3390\/cancers12020407","article-title":"Multiple myeloma: Available therapies and causes of drug resistance","volume":"12","author":"Pinto","year":"2020","journal-title":"Cancers"},{"issue":"1","key":"10.1016\/j.critrevonc.2024.104560_bib53","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1146\/annurev-pathol-012414-040312","article-title":"Driver and passenger mutations in cancer","volume":"10","author":"Pon","year":"2015","journal-title":"Annu. Rev. Pathol.: Mech. Dis."},{"key":"10.1016\/j.critrevonc.2024.104560_bib54","doi-asserted-by":"crossref","DOI":"10.1182\/blood.2023019758","article-title":"Resolving therapy resistance mechanisms in multiple myeloma by multi-omics subclone analysis.","author":"Poos","year":"2023","journal-title":"Blood J., 0000100436"},{"issue":"8","key":"10.1016\/j.critrevonc.2024.104560_bib55","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1002\/ajh.26590","article-title":"Multiple myeloma: 2022 update on diagnosis, risk stratification, and management","volume":"97","author":"Rajkumar","year":"2022","journal-title":"Am. J. Hematol."},{"issue":"1","key":"10.1016\/j.critrevonc.2024.104560_bib56","doi-asserted-by":"crossref","first-page":"4517","DOI":"10.1038\/s41467-022-32145-y","article-title":"The spatio-temporal evolution of multiple myeloma from baseline to relapse-refractory states","volume":"13","author":"Rasche","year":"2022","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.critrevonc.2024.104560_bib57","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1146\/annurev-cancerbio-042516-011348","article-title":"Deciphering genetic intratumor heterogeneity and its impact on cancer evolution","volume":"1","author":"Rosenthal","year":"2017","journal-title":"Annu. Rev. Cancer Biol."},{"issue":"1","key":"10.1016\/j.critrevonc.2024.104560_bib58","doi-asserted-by":"crossref","first-page":"1917","DOI":"10.1038\/s41467-020-15740-9","article-title":"Timing the initiation of multiple myeloma","volume":"11","author":"Rustad","year":"2020","journal-title":"Nat. Commun."},{"issue":"7","key":"10.1016\/j.critrevonc.2024.104560_bib59","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/biomedicines10071674","article-title":"Tracking clonal evolution of multiple myeloma using targeted next-generation DNA sequencing","volume":"10","author":"Salomon-Perzy\u0144ski","year":"2022","journal-title":"Biomedicines"},{"issue":"1","key":"10.1016\/j.critrevonc.2024.104560_bib60","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41467-021-21177-5","article-title":"Biallelic loss of BCMA as a resistance mechanism to CAR T cell therapy in a patient with multiple myeloma","volume":"12","author":"Samur","year":"2021","journal-title":"Nat. Commun."},{"issue":"14","key":"10.1016\/j.critrevonc.2024.104560_bib61","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1182\/blood.2022017094","article-title":"High-dose melphalan treatment significantly increases mutational burden at relapse in multiple myeloma","volume":"141","author":"Samur","year":"2023","journal-title":"Blood"},{"issue":"July","key":"10.1016\/j.critrevonc.2024.104560_bib62","first-page":"1","article-title":"The role of clonal evolution on progression, blood parameters, and response to therapy in multiple myeloma","volume":"12","author":"Sandmann","year":"2022","journal-title":"Front. Oncol."},{"issue":"6","key":"10.1016\/j.critrevonc.2024.104560_bib63","doi-asserted-by":"crossref","DOI":"10.3390\/ijerph20065128","article-title":"Reconstructing clonal evolution\u2014a systematic evaluation of current bioinformatics approaches","volume":"20","author":"Sandmann","year":"2023","journal-title":"Int. J. Environ. Res. Public Health"},{"issue":"4","key":"10.1016\/j.critrevonc.2024.104560_bib64","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1038\/nrg.2016.170","article-title":"The evolution of tumour phylogenetics: principles and practice","volume":"18","author":"Schwartz","year":"2017","journal-title":"Nat. Rev. Genet."},{"issue":"1","key":"10.1016\/j.critrevonc.2024.104560_bib65","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1186\/s12920-014-0064-y","article-title":"FLAGS, frequently mutated genes in public exomes","volume":"7","author":"Shyr","year":"2014","journal-title":"BMC Med. Genom."},{"issue":"21","key":"10.1016\/j.critrevonc.2024.104560_bib66","doi-asserted-by":"crossref","first-page":"2007","DOI":"10.1182\/blood.V124.21.2007.2007","article-title":"Differential and limited expression of mutant alleles in multiple myeloma","volume":"124","author":"Sperling","year":"2014","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.critrevonc.2024.104560_bib67","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1002\/path.5912","article-title":"An overview of mutational and copy number signatures in human cancer","volume":"257","author":"Steele","year":"2022","journal-title":"J. Pathol."},{"issue":"1","key":"10.1016\/j.critrevonc.2024.104560_bib68","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.cell.2010.11.055","article-title":"Massive genomic rearrangement acquired in a single catastrophic event during cancer development","volume":"144","author":"Stephens","year":"2011","journal-title":"Cell"},{"issue":"2","key":"10.1016\/j.critrevonc.2024.104560_bib69","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1158\/1078-0432.CCR-22-2088","article-title":"Mechanisms of MCL-1 protein stability induced by MCL-1 antagonists in B-cell malignancies","volume":"29","author":"Tantawy","year":"2023","journal-title":"Clin. Cancer Res."},{"issue":"2","key":"10.1016\/j.critrevonc.2024.104560_bib70","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1038\/s41592-020-01013-2","article-title":"A practical guide to cancer subclonal reconstruction from DNA sequencing","volume":"18","author":"Tarabichi","year":"2021","journal-title":"Nat. Methods"},{"issue":"18","key":"10.1016\/j.critrevonc.2024.104560_bib71","doi-asserted-by":"crossref","first-page":"1","DOI":"10.15252\/embj.2021108389","article-title":"Cancer evolution: darwin and beyond","volume":"40","author":"Vendramin","year":"2021","journal-title":"EMBO J."},{"issue":"1","key":"10.1016\/j.critrevonc.2024.104560_bib72","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41467-022-31430-0","article-title":"The genetic heterogeneity and drug resistance mechanisms of relapsed refractory multiple myeloma","volume":"13","author":"Vo","year":"2022","journal-title":"Nat. Commun."},{"issue":"6","key":"10.1016\/j.critrevonc.2024.104560_bib73","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1182\/blood-2018-03-840132","article-title":"Identification of novel mutational drivers reveals oncogene dependencies in multiple myeloma","volume":"132","author":"Walker","year":"2018","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.critrevonc.2024.104560_bib74","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1038\/leu.2013.199","article-title":"Intraclonal heterogeneity is a critical early event in the development of myeloma and precedes the development of clinical symptoms","volume":"28","author":"Walker","year":"2014","journal-title":"Leukemia"},{"key":"10.1016\/j.critrevonc.2024.104560_bib75","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms7997","article-title":"APOBEC family mutational signatures are associated with poor prognosis translocations in multiple myeloma","volume":"6","author":"Walker","year":"2015","journal-title":"Nat. Commun."},{"issue":"13","key":"10.1016\/j.critrevonc.2024.104560_bib76","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1182\/blood-2016-06-723007","article-title":"Clonal selection and double-hit events involving tumor suppressor genes underlie relapse in myeloma","volume":"128","author":"Weinhold","year":"2016","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.critrevonc.2024.104560_bib77","doi-asserted-by":"crossref","DOI":"10.1038\/oncsis.2017.36","article-title":"Molecular signaling in multiple myeloma: Association of RAS\/RAF mutations and MEK\/ERK pathway activation","volume":"6","author":"Xu","year":"2017","journal-title":"Oncogenesis"},{"issue":"2","key":"10.1016\/j.critrevonc.2024.104560_bib78","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1182\/bloodadvances.2021004992","article-title":"Clonal phylogeny and evolution of critical cytogenetic aberrations in multiple myeloma at single-cell level by QM-FISH","volume":"6","author":"Yan","year":"2022","journal-title":"Blood Adv."},{"issue":"1","key":"10.1016\/j.critrevonc.2024.104560_bib79","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s43856-023-00380-z","article-title":"Selective MCL-1 inhibitor ABBV-467 is efficacious in tumor models but is associated with cardiac troponin increases in patients","volume":"3","author":"Yuda","year":"2023","journal-title":"Commun. Med."},{"issue":"5","key":"10.1016\/j.critrevonc.2024.104560_bib80","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1182\/bloodadvances.2019000779","article-title":"Integrative analysis of the genomic and transcriptomic landscape of double-refractory multiple myeloma","volume":"4","author":"Ziccheddu","year":"2020","journal-title":"Blood Adv."}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842824003032?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842824003032?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T10:22:48Z","timestamp":1778581368000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842824003032"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":80,"alternative-id":["S1040842824003032"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2024.104560","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A systematic literature review on clonal evolution events preceding relapse in multiple myeloma","name":"articletitle","label":"Article Title"},{"value":"Critical Reviews in Oncology\/Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.critrevonc.2024.104560","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"104560"}}